Federal Register / Vol. 82, No. 249 / Friday, December 29, 2017 / Notices 61759 

assets equal to $250 billion or more; (ii) 

have total consolidated on-balance sheet 

foreign exposure equal to $10 billion or 

more; or (iii) have total consolidated 

assets equal to $10 billion or more and 

are a consolidated subsidiary of one of 

the following: (A) a covered depository 

institution holding company or 

depository institution that has total 

assets equal to $250 billion or more; (B) 

a covered depository institution holding 

company or depository institution that 

has total consolidated on-balance sheet 

foreign exposure equal to $10 billion or 

more; or (C) a company that has been 

designated by the Financial Stability 

Oversight Council for supervision by the 

Federal Reserve Board. 

Burden Estimate: 

SUMMARY OF ANNUAL BURDEN

Type of burden Obligation to 

respond 

Estimated 

number of 

respondents 

Estimated 

frequency of 

responses 

Estimated time 

per response 

Frequency of 

response 

Total annual 

estimated 

burden 

Liquidity Coverage Ratio (LCR)—12 

CFR 329.40(a), (b).

Reporting ........... Mandatory .......... ........................ ........................ ........................ ............................ ........................

§ 329.40(a) Notification that liquidity 

coverage ratio is less than minimum in § 329.10.

Reporting ........... Mandatory .......... 2 12 0.25 On Occasion ...... 6.00 

§ 329.40(b) Notification that liquidity 

coverage ratio is less than minimum in § 329.10 for 3 consecutive days or otherwise noncompliant.

Reporting ........... Mandatory .......... 2 1 0.25 On Occasion ...... 0.50 

§ 329.40(b) Plan for achieving compliance.Recordkeeping ... Mandatory .......... 2 1 100.00 On Occasion ...... 200.00 

§ 329.40(b)(4) Weekly report of 

progress toward achieving compliance.

Reporting ........... Mandatory .......... 2 4 0.25 On Occasion ...... 2.00 

Liquidity Coverage Ratio (LCR)—12 

CFR 329.22(a)(2), (5).

Recordkeeping ... Mandatory .......... ........................ ........................ ........................ ............................ ........................

§ 329.22(a)(2) Policies that require 

eligible HQLA to be under control 

of liquidity risk management function.

Recordkeeping ... Mandatory .......... 2 1 10.00 On Occasion ...... 20.00 

§ 329.22(a)(5) Documented methodology providing consistent treatment for determining whether eligible HQLA meets operational requirements.

Recordkeeping ... Mandatory .......... 2 1 10.00 On Occasion ...... 20.00 

Total Hourly Burden .................. ............................ ............................ ........................ ........................ ........................ ............................ 248.50 

General Description of Collection: The 

LCR rule implements a quantitative 

liquidity requirement and contains 

requirements subject to the PRA. The 

reporting and recordkeeping 

requirements are found in Sections 

329.22 and 329.40. The requirement is 

designed to promote the short-term 

resilience of the liquidity risk profile of 

large and internationally active banking 

organizations, thereby improving the 

banking sector’s ability to absorb shocks 

arising from financial and economic 

stress, and to further improve the 

measurement and management of 

liquidity risk. The LCR rule establishes 

a quantitative minimum liquidity 

coverage ratio that requires a company 

subject to the rule to maintain an 

amount of high-quality liquid assets (the 

numerator of the ratio) that is no less 

than 100 percent of its total net cash 

outflows over a prospective 30 calendarday period (the denominator of the 

ratio). 

The FDIC has reviewed its previous 

PRA submission and has updated its 

methodology for calculating the burden 

in order to be consistent with the Office 

of the Controller of the Currency and the 

Federal Reserve Board. The overall 

increase in burden hours is the result of 

these changes. 

Request for Comment 

Comments are invited on: (a) Whether 

the collections of information are 

necessary for the proper performance of 

the FDIC’s functions, including whether 

the information has practical utility; (b) 

the accuracy of the estimates of the 

burden of the information collections, 

including the validity of the 

methodology and assumptions used; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collections of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. All comments will become 

a matter of public record. 

Dated at Washington, DC, on December 22, 

2017. 

Federal Deposit Insurance Corporation. 

Valerie J. Best, 

Assistant Executive Secretary. 

[FR Doc. 2017–28138 Filed 12–28–17; 8:45 am] 

BILLING CODE 6714–01–P 

FEDERAL TRADE COMMISSION 

[File No. 171 0140] 

Becton, Dickinson and Company and 

C. R. Bard; Analysis To Aid Public 

Comment 

AGENCY: Federal Trade Commission. 

ACTION: Proposed Consent Agreement. 

SUMMARY: The consent agreement in this 

matter settles alleged violations of 

federal law prohibiting unfair methods 

of competition. The attached Analysis to 

Aid Public Comment describes both the 

allegations in the complaint and the 

terms of the consent orders—embodied 

in the consent agreement—that would 

settle these allegations. 

DATES: Comments must be received on 

or before January 23, 2018. 

ADDRESSES: Interested parties may file a 

comment online or on paper, by 

following the instructions in the 

Request for Comment part of the 

SUPPLEMENTARY INFORMATION section 

below. Write: ‘‘In the Matter of Becton 

Dickinson and Co./Bard, Inc., File No. 

171 0140’’ on your comment, and file 

your comment online at https://

ftcpublic.commentworks.com/ftc/ 


ethrower on DSK3G9T082PROD with NOTICES
61760 Federal Register / Vol. 82, No. 249 / Friday, December 29, 2017 / Notices 

bectondickinsonconsent by following 

the instructions on the web-based form. 

If you prefer to file your comment on 

paper, write ‘‘In the Matter of Becton 

Dickinson and Co./Bard, Inc., File No. 

171 0140’’ on your comment and on the 

envelope, and mail your comment to the 

following address: Federal Trade 

Commission, Office of the Secretary, 

600 Pennsylvania Avenue NW, Suite 

CC–5610 (Annex D), Washington, DC 

20580, or deliver your comment to the 

following address: Federal Trade 

Commission, Office of the Secretary, 

Constitution Center, 400 7th Street SW, 

5th Floor, Suite 5610 (Annex D), 

Washington, DC 20024. 

FOR FURTHER INFORMATION CONTACT: 

Jared Nagley, Attorney, (212–607–2813) 

and Geralyn Trujillo, Attorney, (212– 

607–2806), Northeast Region, One 

Bowling Green, Suite 318, New York, 

New York 10004. 

SUPPLEMENTARY INFORMATION: Pursuant 

to Section 6(f) of the Federal Trade 

Commission Act, 15 U.S.C. 46(f), and 

FTC Rule 2.34, 16 CFR 2.34, notice is 

hereby given that the above-captioned 

consent agreement containing a consent 

order to cease and desist, having been 

filed with and accepted, subject to final 

approval, by the Commission, has been 

placed on the public record for a period 

of thirty (30) days. The following 

Analysis to Aid Public Comment 

describes the terms of the consent 

agreement, and the allegations in the 

complaint. An electronic copy of the 

full text of the consent agreement 

package can be obtained from the FTC 

Home Page (for December 22, 2017), on 

the World Wide Web, at https://

www.ftc.gov/news-events/commissionactions. 

You can file a comment online or on 

paper. For the Commission to consider 

your comment, we must receive it on or 

before January 23, 2018. Write ‘‘In the 

Matter of Becton Dickinson and Co./ 

Bard, Inc., File No. 171 0140’’ on your 

comment. Your comment—including 

your name and your state—will be 

placed on the public record of this 

proceeding, including, to the extent 

practicable, on the public Commission 

website, at https://www.ftc.gov/policy/ 

public-comments. 

Postal mail addressed to the 

Commission is subject to delay due to 

heightened security screening. As a 

result, we encourage you to submit your 

comments online. To make sure that the 

Commission considers your online 

comment, you must file it at https://

ftcpublic.commentworks.com/ftc/ 

bectondickinsonconsent by following 

the instructions on the web-based form. 

If this Notice appears at http://

www.regulations.gov/#!home, you also 

may file a comment through that 

website. 

If you prefer to file your comment on 

paper, write ‘‘In the Matter of Becton 

Dickinson and Co./Bard, Inc., File No. 

171 0140’’ on your comment and on the 

envelope, and mail your comment to the 

following address: Federal Trade 

Commission, Office of the Secretary, 

600 Pennsylvania Avenue NW, Suite 

CC–5610 (Annex D), Washington, DC 

20580, or deliver your comment to the 

following address: Federal Trade 

Commission, Office of the Secretary, 

Constitution Center, 400 7th Street SW, 

5th Floor, Suite 5610 (Annex D), 

Washington, DC 20024. If possible, 

submit your paper comment to the 

Commission by courier or overnight 

service. 

Because your comment will be placed 

on the publicly accessible FTC website 

at https://www.ftc.gov, you are solely 

responsible for making sure that your 

comment does not include any sensitive 

or confidential information. In 

particular, your comment should not 

include any sensitive personal 

information, such as your or anyone 

else’s Social Security number; date of 

birth; driver’s license number or other 

state identification number, or foreign 

country equivalent; passport number; 

financial account number; or credit or 

debit card number. You are also solely 

responsible for making sure that your 

comment does not include any sensitive 

health information, such as medical 

records or other individually 

identifiable health information. In 

addition, your comment should not 

include any ‘‘trade secret or any 

commercial or financial information 

which . . . is privileged or 

confidential’’—as provided by Section 

6(f) of the FTC Act, 15 U.S.C. 46(f), and 

FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)— 

including in particular competitively 

sensitive information such as costs, 

sales statistics, inventories, formulas, 

patterns, devices, manufacturing 

processes, or customer names. 

Comments containing material for 

which confidential treatment is 

requested must be filed in paper form, 

must be clearly labeled ‘‘Confidential,’’ 

and must comply with FTC Rule 4.9(c). 

In particular, the written request for 

confidential treatment that accompanies 

the comment must include the factual 

and legal basis for the request, and must 

identify the specific portions of the 

comment to be withheld from the public 

record. See FTC Rule 4.9(c). Your 

comment will be kept confidential only 

if the General Counsel grants your 

request in accordance with the law and 

the public interest. Once your comment 

has been posted on the public FTC 

website—as legally required by FTC 

Rule 4.9(b)—we cannot redact or 

remove your comment from the FTC 

website, unless you submit a 

confidentiality request that meets the 

requirements for such treatment under 

FTC Rule 4.9(c), and the General 

Counsel grants that request. 

Visit the FTC website at http://

www.ftc.gov to read this Notice and the 

news release describing it. The FTC Act 

and other laws that the Commission 

administers permit the collection of 

public comments to consider and use in 

this proceeding, as appropriate. The 

Commission will consider all timely 

and responsive public comments that it 

receives on or before January 23, 2018. 

For information on the Commission’s 

privacy policy, including routine uses 

permitted by the Privacy Act, see 

https://www.ftc.gov/site-information/ 

privacy-policy. 

Analysis of Agreement Containing 

Consent Orders To Aid Public Comment 

I. Introduction 

The Federal Trade Commission 

(‘‘Commission’’) has accepted, subject to 

final approval, an Agreement 

Containing Consent Orders (‘‘Consent 

Agreement’’) from Becton, Dickinson 

and Company (‘‘BD’’) and C. R. Bard, 

Inc. (‘‘Bard’’) (collectively, the 

‘‘Respondents’’) that is designed to 

remedy the anticompetitive effects that 

would likely result from BD’s proposed 

acquisition of Bard. The proposed 

Decision and Order (‘‘Order’’) requires 

the Respondents to divest all rights and 

assets related to Bard’s tunneled home 

drainage catheter business and BD’s soft 

tissue core needle biopsy device 

business to Merit Medical Systems, Inc. 

(‘‘Merit’’). The Order To Maintain 

Assets requires Respondents to maintain 

the viability and competitiveness of the 

businesses pending divestiture. 

Pursuant to an Agreement and Plan of 

Merger, dated as of April 23, 2017, BD 

and Lambda Corp., a wholly-owned 

subsidiary of BD, will acquire the issued 

and outstanding shares of Bard by 

means of a merger in exchange for cash 

and stock valued at approximately $24 

billion (the ‘‘Acquisition’’). The 

Commission’s Complaint alleges that 

the proposed Acquisition, if 

consummated, would violate Section 7 

of the Clayton Act, as amended, 15 

U.S.C. 18, and Section 5 of the Federal 

Trade Commission Act, as amended, 15 

U.S.C. 45, by substantially lessening 

competition in the U.S. markets for 

tunneled home drainage catheter 

systems and soft tissue core needle 

biopsy devices. The Consent Agreement 


ethrower on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 82, No. 249 / Friday, December 29, 2017 / Notices 61761 

is designed to remedy the alleged 

violations by preserving the competition 

that otherwise would be lost in these 

markets as a result of the proposed 

Acquisition. 

The Commission has placed the 

Consent Agreement on the public record 

for 30 days to solicit comments from 

interested persons. Comments received 

during this period will become part of 

the public record. After 30 days, the 

Commission will again review the 

Consent Agreement, along with any 

comments received, and decide whether 

it should withdraw from the Consent 

Agreement, modify the Consent 

Agreement or Order, or make the Order 

final. 

II. The Respondents 

BD, headquartered in Franklin Lakes, 

New Jersey, is a medical technology 

company that manufactures and sells a 

broad range of medical supplies, 

devices, laboratory equipment, and 

diagnostic products throughout the 

world. Its operations consist of two 

business segments: BD Medical and BD 

Life Sciences. BD Medical provides a 

broad array of medical technologies and 

devices to hospitals, clinics, physicians’ 

office practices, pharmacies, 

pharmaceutical companies, and 

healthcare workers. 

Bard, headquartered in Murray Hill, 

New Jersey, is a medical technology 

company that manufactures medical, 

surgical, diagnostic, and patient care 

devices sold to hospitals, healthcare 

professionals, extended care facilities, 

and other medical facilities throughout 

the world. Its operations consist of four 

principal divisions: Bard Access 

Systems, Inc., Bard Medical Division, 

Bard Peripheral Vascular, Inc., and Bard 

Biopsy Systems. 

III. The Relevant Markets and 

Structure of the Markets 

A. Tunneled Home Drainage Catheter 

Systems 

Tunneled home drainage catheter 

systems are medical devices used to 

treat recurrent fluid buildup in the 

lungs and abdomen, conditions known 

as pleural effusions and malignant 

ascites, respectively. Patients suffering 

from these conditions, often due to 

cancer or other serious illnesses, 

commonly require frequent fluid 

drainage. Tunneled home drainage 

catheter systems drain fluid from the 

lungs (pleural drainage) or abdomen 

(peritoneal drainage) through a 

tunneled, indwelling catheter connected 

to a disposable receptacle. After a 

medical doctor places the indwelling 

catheter, the device allows fluid 

drainage to take place conveniently in a 

patient’s home or in a hospice setting 

where the patient or a caregiver can 

attach, remove, replace, and dispose of 

the drainage receptacle as frequently as 

needed. Although patients requiring 

pleural or peritoneal drainage can 

undergo an outpatient medical 

procedure when fluid build-up becomes 

severe, such procedures are not suitable 

alternatives to tunneled home drainage 

catheter systems, because they require a 

patient to make repeated trips to a 

healthcare facility to see a doctor. 

Customers likely would not substitute 

outpatient medical procedures in 

response to a small but significant 

increase in the price of tunneled home 

drainage catheter systems. 

BD and Bard are the two largest 

manufacturers of tunneled home 

drainage catheter systems in the United 

States, with a combined market share of 

approximately 98%. The remaining 

market share is divided between Rocket 

Medical plc (‘‘Rocket Medical’’) and B. 

Braun Medical Inc. (‘‘B. Braun’’). Rocket 

Medical is a new entrant to the U.S. 

market, and both Rocket Medical and B. 

Braun, in addition to having a much 

smaller share of the market than BD and 

Bard, have far less recognition among 

U.S. customers. 

B. Soft Tissue Core Needle Biopsy 

Devices 

Soft tissue core needle biopsy devices 

are used by medical clinicians, typically 

interventional radiologists or 

oncologists, to remove small samples of 

tissue from soft tissue organs for 

examination and diagnosis. There are no 

practical alternatives to soft tissue core 

needle biopsy devices for clinicians 

seeking to perform a soft tissue biopsy. 

Other biopsy devices, such as bone or 

bone marrow biopsy devices, are not 

approved or intended to be used for soft 

tissue biopsies. Soft tissue core needle 

biopsy devices do not include, and are 

distinguished from, vacuum-assisted 

biopsy (‘‘VAB’’) devices which employ 

a vacuum to remove larger tissue 

samples. VAB devices are used for 

breast biopsies involving lesions that are 

difficult to locate and are not used to 

perform biopsies of other soft tissues 

and organs. VAB devices are more 

complex devices that are sold at a 

significantly higher price than soft 

tissue core needle biopsy devices. 

Accordingly, customers likely would 

not switch to VAB devices in response 

to a small but significant increase in the 

price of soft tissue core needle biopsy 

devices. 

Bard and BD are the two largest 

manufacturers of soft tissue core needle 

biopsy devices in the United States, 

with a combined market share of 60% 

or greater. Other participants in the 

market include Cook Medical, Argon 

Medical Devices, Inc., and Hologic, Inc., 

but each of these manufacturers has a 

smaller market share than either Bard or 

BD. In addition, there is a fringe of other 

manufacturers with very small market 

shares. 

C. The Relevant Geographic Market 

The relevant geographic market for 

both tunneled home drainage catheter 

systems and soft tissue core needle 

biopsy devices is the United States. 

These relevant products are medical 

devices regulated by the U.S. Food and 

Drug Administration (‘‘FDA’’). Medical 

devices sold outside of the United 

States, but not approved for sale in the 

United States, are not viable competitive 

alternatives for U.S. consumers. 

IV. Competitive Effects of the 

Transaction 

The proposed Acquisition would 

likely substantially lessen competition 

in the U.S. markets for tunneled home 

drainage catheter systems and soft tissue 

core needle biopsy devices. The 

Acquisition would combine the largest 

and second-largest suppliers of both 

products in the United States and would 

substantially increase concentration in 

already highly concentrated markets. 

Under the Horizontal Merger 

Guidelines, the Acquisition would 

presumptively create or enhance market 

power. By eliminating direct and 

substantial competition between 

Respondents, the proposed Acquisition 

likely would allow the combined firm to 

exercise market power unilaterally, 

resulting in higher prices and/or 

reduced innovation. 

V. Entry 

Entry in the relevant markets would 

not be timely, likely, or sufficient in 

magnitude, character, and scope to deter 

or counteract the anticompetitive effects 

of the proposed Acquisition. New entry 

into the markets for each of these 

devices is difficult, time-consuming, 

and expensive, requiring a significant 

investment of time and money for 

product research and development, 

regulatory approval by the FDA, and the 

establishment of a sales and marketing 

infrastructure sufficient to develop 

customer awareness and acceptance of 

the products. 

VI. The Proposed Consent Agreement 

The Consent Agreement remedies the 

competitive concerns raised by the 

proposed Acquisition by requiring the 

Respondents to divest all of the assets, 

facilities, and resources relating to 


ethrower on DSK3G9T082PROD with NOTICES
61762 Federal Register / Vol. 82, No. 249 / Friday, December 29, 2017 / Notices 

Bard’s tunneled home drainage catheter 

systems business and BD’s soft tissue 

core needle biopsy devices business to 

Merit. The provisions of the Consent 

Agreement will enable Merit to become 

an independent, viable, and effective 

competitor in the respective relevant 

markets and maintain the competition 

that currently exists. 

Merit, headquartered in South Jordan, 

Utah, is a global company with 30 years 

of experience in the development, 

manufacture, and distribution of 

medical devices used in interventional, 

diagnostic, and therapeutic procedures. 

Merit offers a portfolio of products that 

is highly complementary to the 

tunneled home drainage catheter 

systems being acquired. Merit also 

recently introduced its first soft tissue 

core needle biopsy device product. 

Merit possesses substantial industry 

expertise in these product areas and 

sells its products to similar customers as 

BD and Bard. For these reasons, Merit 

is well positioned to restore the benefits 

of competition that would be lost due to 

the Acquisition. 

Pursuant to the Order, Merit will 

receive all rights and assets related to 

Bard’s tunneled home drainage catheter 

system business and BD’s soft tissue 

core needle biopsy device business, 

including all of the confidential 

business information used in those 

businesses. Merit will own or receive a 

license to all intellectual property 

necessary to run the businesses. It will 

also acquire the equipment used in the 

manufacturing of the products and all 

documentation and other information 

related to the products. Respondents 

will also contract manufacture products 

for Merit until it is able to manufacture 

them itself, and Respondents will 

provide transitional services to Merit to 

assist the company in establishing 

manufacturing capabilities for the 

divested products. 

The Respondents must accomplish 

the divestitures no later than 10 days 

after the consummation of the proposed 

Acquisition. If the Commission 

determines that Merit is not an 

acceptable acquirer, or that the manner 

of the divestitures is not acceptable, the 

proposed Order requires the 

Respondents to unwind the sale of 

assets to Merit and then divest the assets 

to a Commission-approved acquirer(s) 

within 180 days of the date the Order 

becomes final. Pursuant to the Order To 

Maintain Assets, Respondents must 

maintain the businesses pending 

divestiture. 

The Commission has agreed to 

appoint a Monitor to ensure that the 

Respondents comply with all of their 

obligations pursuant to the Consent 

Agreement and to keep the Commission 

informed about the status of the transfer 

of assets to Merit. The Commission has 

appointed Mazars LLP as the Monitor in 

this matter. The proposed Order further 

allows the Commission to appoint a 

trustee in the event the parties fail to 

divest the products as required. 

VII. Opportunity for Public Comment 

The purpose of this analysis is to 

facilitate public comment on the 

Consent Agreement to aid the 

Commission in determining whether it 

should make the Order final. This 

analysis is not intended to constitute an 

official interpretation of the proposed 

Consent Agreement and does not 

modify its terms in any way. 

By direction of the Commission. 

April J. Tabor, 

Acting Secretary. 

[FR Doc. 2017–28213 Filed 12–28–17; 8:45 am] 

BILLING CODE 6750–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–R–262] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, HHS. 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, and to allow 

a second opportunity for public 

comment on the notice. Interested 

persons are invited to send comments 

regarding the burden estimate or any 

other aspect of this collection of 

information, including the necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions, the accuracy of 

the estimated burden, ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and the use 

of automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments on the collection(s) of 

information must be received by the 

OMB desk officer by January 29, 2018. 

ADDRESSES: When commenting on the 

proposed information collections, 

please reference the document identifier 

or OMB control number. To be assured 

consideration, comments and 

recommendations must be received by 

the OMB desk officer via one of the 

following transmissions: OMB, Office of 

Information and Regulatory Affairs, 

Attention: CMS Desk Officer, Fax 

Number: (202) 395–5806 OR, Email: 

OIRA_submission@omb.eop.gov. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, you may make your request 

using one of following: 

1. Access CMS’ website address at 

https://www.cms.gov/Regulations-andGuidance/Legislation/ 

PaperworkReductionActof1995/PRAListing.html. 

2. Email your request, including your 

address, phone number, OMB number, 

and CMS document identifier, to 

Paperwork@cms.hhs.gov. 

3. Call the Reports Clearance Office at 

(410) 786–1326. 

FOR FURTHER INFORMATION CONTACT: 

William Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. The term ‘‘collection of 

information’’ is defined in 44 U.S.C. 

3502(3) and 5 CFR 1320.3(c) and 

includes agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires federal agencies 

to publish a 30-day notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension or 

reinstatement of an existing collection 

of information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, CMS is 

publishing this notice that summarizes 

the following proposed collection(s) of 

information for public comment: 

1. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Contract Year 

2019 Plan Benefit Package (PBP) 

Software and Formulary Submission; 

Use: We require that Medicare 


ethrower on DSK3G9T082PROD with NOTICES